Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AXS 17

Next Previous
Drug Profile

AXS 17

Alternative Names: AXS-17; AZ-7325; AZD-7325; BAER 101

Latest Information Update: 26 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; University College London
  • Developer AstraZeneca; Avenue Therapeutics; Cincinnati Childrens Hospital Medical Center; University College London
  • Class Antiepileptic drugs; Anxiolytics; Behavioural disorder therapies; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action GABA A alpha 2 receptor modulators; GABA A alpha 3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anxiety disorders
  • Preclinical Absence epilepsy
  • No development reported Autism spectrum disorder; Fragile X syndrome; Neurological disorders

Most Recent Events

  • 06 Nov 2025 Axsome Therapeutics plans a phase II trial-enabling activities for the Epilepsy in 2026
  • 06 Nov 2025 Baergic Bio has been acquired and merged into Axsome Therapeutics
  • 06 Nov 2025 AZD 7325 licensed to Axsome Therapeutics worldwide for the treatment of Epilepsy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top